CURRENT
ISSUE
1594
March 23, 2020
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.1,2 IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
More from Issue 1594
Previous Issue: 1593 March 9, 2020
- Peanut Allergen Powder (Palforzia)
- Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
- Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
- Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
- Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
Coming Soon
Trijardy XR - A Combination of 3 Old Drugs for Type 2 Diabetes
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol
Cefiderocol (Fetroja) for Complicated Urinary Tract Infections
Donate
Subscribe
ADVANCE
RELEASE
RELEASE
The rapid spread and severity of COVID-19 (caused
by SARS-CoV-2) have raised some questions about
use of various drugs in patients with the disease and
whether currently available drugs could be effective
in treating it. Definitive answers are lacking, but some
recommendations can be made. Updated information
on COVID-19 is available from the CDC at www.cdc. ... Continue reading
Tweets
